Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

Delayed Quote. Delayed  - 05/22 08:57:15 pm
134.095 USD   +2.03%
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVE : Csco, incy
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2017 05/17/2017 05/18/2017 05/19/2017 05/22/2017 Date
117.76(c) 120.49(c) 128.8(c) 131.43(c) 134.095 Last
2 682 494 3 733 581 5 666 349 3 856 544 1 524 873 Volume
+0.35% +2.32% +6.90% +2.04% +2.03% Change
More quotes
Financials ($)
Sales 2017 1 428 M
EBIT 2017 -64,7 M
Net income 2017 -134 M
Finance 2017 268 M
Yield 2017 -
Sales 2018 1 618 M
EBIT 2018 141 M
Net income 2018 88,9 M
Finance 2018 635 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 333,41
EV / Sales2017 18,7x
EV / Sales2018 16,2x
Capitalization 26 914 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology.Its product, Jakafi, a JAK1 and JAK2 inhibitor, is... 
Sector
Biotechnology & Medical Research
Calendar
05/22 | 05:30pmPresentation
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVERS : Csco, incy
05/17 INCYTE : First Data from Combination of Epacadostat with Opdivo® (nivolumab) Wil..
05/17 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/04 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
05/04 INCYTE : reports 1Q loss
05/04 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
05/04 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
05/04 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
More news
Sector news : Biotechnology & Medical Research - NEC
03:18p Cross-border M&A between U.S. and European firms at 10 year high
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
05/07 REGENERON PHARMACEUTICALS : shares poised for rebound - Barron's
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05:37p.@JimCramer's got some advice for Gilead - and it has to do with Incyte.
1
05:33pImpressive $INCY Jakafi growth along with therapeutic opportunities and pipel.. 
05:31p$INCY Slideshow from BAML Conference:  
05:00pIncyte Corporation (INCY) Presents At Bank of America Merrill Lynch 2017 Heal.. 
04:11p$INCY aggressive buys 500 June $135 calls
2
More tweets
Qtime:52
News from SeekingAlpha
11:00a Incyte Corporation (INCY) Presents At Bank of America Merrill Lynch 2017 Heal..
07:30a Gilead Should Buy Incyte - Cramer's Lightning Round (5/19/17)
05/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 21, 2017
05/19 Incyte Corporation 2017 Q1 - Results - Earnings Call Slides
05/19 Asco Preview - Breast Cancer And I-O Combos Grab The Early Headlines
Advertisement
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 145 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION31.08%26 914
QUINTILES IMS HOLDINGS..9.20%18 274
LONZA GROUP AG18.67%15 134
CELLTRION, INC.--.--%10 399
SEATTLE GENETICS, INC.26.21%9 505
ALKERMES PLC4.19%8 871
More Results